Tigermed Reports 14% Revenue Growth Amid Global R&D Expansion

The company’s financial performance highlights a 14.1% year-over-year revenue increase, supported by robust growth in its clinical trial solutions segment, which reached RMB 1.77 billion. Domestic operations in China remained the primary driver with RMB 2.11 billion in revenue, reflecting a 24% increase compared to the same period last year. Meanwhile, Tigermed expanded its specialized capabilities by acquiring Teddy Laboratory and Shanghai Bioquick, moves designed to bolster its end-to-end service chain from preclinical testing to clinical supply.

Operational milestones in the first half of the year included the launch of a new global headquarters in Hangzhou and the commencement of operations at a 4,300-square-meter CDMO manufacturing facility in Exton, U.S. The company continues to prioritize digital transformation, adding 30 new decentralized clinical trial projects and deploying proprietary AI agents to streamline research. With 11,984 employees globally, Tigermed remains the only Chinese clinical CRO to maintain a position among the world's top 10 firms, currently managing 667 ongoing drug clinical research projects.